Cancer Therapy News and Research

RSS

Cancer Research UK launches new Centre in Glasgow

Cancer Research UK today (Thursday) launches a new Centre which will accelerate the pace of research in Glasgow and see the city become a world leader in the development of new treatments tailored for individual cancer patients.

21 Jan 2011

How genetic abnormalities transform normal cells into leukemic cells

Cancer scientists led by Dr. John Dick at the Ontario Cancer Institute (OCI) and collaborators at St Jude Children's Research Hospital (Memphis) have found that defective genes and the individual leukemia cells that carry them are organized in a more complex way than previously thought.

21 Jan 2011

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

In a new study in which Precision Therapeutics' Multi-Gene Predictors were independently validated by investigators at US Oncology and MD Anderson, Precision highlights the potential role of the ChemoFx® in vitro chemosensitivity test and multi-gene predictors in determining a patient's likelihood of response to multi-drug chemotherapy regimens in breast cancer.

21 Jan 2011

Scientists decipher genetic code for a pancreatic cancer type

Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors. The work, described online in the Jan. 20 issue of Science Express, shows that patients whose tumors have certain coding "mistakes" live twice as long as those without them.

21 Jan 2011

Breastfeeding can partially offset long-term side effects of cancer treatment

Women who have survived childhood cancer should be advised to breastfeed if they can, in order to offset some of the negative health effects of their earlier cancer treatment. According to Susan Ogg and colleagues from St. Jude Children's Research Hospital in Memphis, Tennessee, making women aware of the benefits of breastfeeding should be part of routine post-cancer diet and healthy lifestyle recommendations.

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

ETPN, Nanobiotix introduce Nanomed TV to provide information on Nanomedicine

Nanomed TV www.dailymotion.com/nanomedTV foresees to become the main hub for Nanomedicine thanks to its initiators, two major European players in nanomedicine: the European Technology Platform on Nanomedicine and Nanobiotix.

20 Jan 2011

MD Anderson receives $150 million grant from Khalifa Foundation for cancer research

The Khalifa bin Zayed Al Nahyan Charity Foundation is granting $150 million to The University of Texas MD Anderson Cancer Center to support genetic-analysis based research, diagnosis and treatment of cancer.

20 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

Diabetes increases risk of death in breast cancer patients

Breast cancer patients are nearly 50 percent more likely to die of any cause if they also have diabetes, according to a comprehensive review of research conducted by Johns Hopkins physicians.

18 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Researchers find kidney-specific gene defects may increase risk of heart failure

Scientists have identified the first DNA sequence variant common in the population that is not only associated with an increased risk of heart failure, but appears to play a role in causing it.

18 Jan 2011

University of Illinois receives Friends of Mel Foundation support grant for Bone Marrow Transplant Program

The University of Illinois is set to receive a grant from the Friends of Mel Foundation (FOM) in support of their Bone Marrow Transplant Program. The program was selected as the recipient of the Mel's Magic award for January 2011. Mel's Magic was created by FOM in May 2009 to familiarize their supporters with other organizations that work tirelessly to make a difference in the cancer community.

14 Jan 2011

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

Kanzius Cancer Research Foundation announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the December 2010 issue of the American Association of Cancer Research's Clinical Cancer Research journal.

14 Jan 2011

20% of cancer survivors experience chronic pain: Study

Surviving cancer may also mean surviving pain, according to a study by the University of Michigan Health System showing 20 percent of cancer survivors at least two years post diagnosis have current cancer-related chronic pain.

13 Jan 2011

Philadelphia CTCA hospital purchases BSD-2000 Hyperthermia System

BSD Medical Corporation announced today that the Cancer Treatment Centers of America (CTCA) hospital at Eastern Regional Medical Center, located in Philadelphia, Pennsylvania, has purchased a BSD-2000 Hyperthermia System (BSD-2000). CTCA in Philadelphia is a state-of-the-art hospital that provides advanced cancer treatments, world-class technologies, and supportive therapies under one roof.

13 Jan 2011

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011.

12 Jan 2011

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.

12 Jan 2011

Cancer Therapy News and Research

Cancer Research UK launches new Centre in Glasgow

How genetic abnormalities transform normal cells into leukemic cells

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

Scientists decipher genetic code for a pancreatic cancer type

Breastfeeding can partially offset long-term side effects of cancer treatment

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

ETPN, Nanobiotix introduce Nanomed TV to provide information on Nanomedicine

MD Anderson receives $150 million grant from Khalifa Foundation for cancer research

Endothelial cells may play a role in controlling cancer behavior: New study

Theraclone, Pfizer enter multi-year research and development collaboration

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Diabetes increases risk of death in breast cancer patients

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Researchers find kidney-specific gene defects may increase risk of heart failure

University of Illinois receives Friends of Mel Foundation support grant for Bone Marrow Transplant Program

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

20% of cancer survivors experience chronic pain: Study

Philadelphia CTCA hospital purchases BSD-2000 Hyperthermia System

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News